prikaz prve stranice dokumenta The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease
  Preuzmi
PDF 2.72 MB
Znanstveni rad - Izvorni znanstveni rad
The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease
Biomedicines, 11 (2023), 4; 1025. https://doi.org/10.3390/biomedicines11041025
Osmanović Barilar, Jelena; Babić Perhoč, Ana; Knezović, Ana; Homolak, Jan; Virag, Davor; Šalković-Petrišić, Melita

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Osmanović Barilar, J., Babić Perhoč, A., Knezović, A., Homolak, J., Virag, D. i Šalković Petrišić, M. (2023). The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease. Biomedicines, 11. (4). doi: 10.3390/biomedicines11041025

Osmanović Barilar, Jelena, et al. "The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease." Biomedicines, vol. 11, br. 4, 2023. https://doi.org/10.3390/biomedicines11041025

Osmanović Barilar, Jelena, Ana Babić Perhoč, Ana Knezović, Jan Homolak, Davor Virag i Melita Šalković Petrišić. "The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease." Biomedicines 11, br. 4 (2023). https://doi.org/10.3390/biomedicines11041025

Osmanović Barilar, J., et al. (2023) 'The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease', Biomedicines, 11(4). doi: 10.3390/biomedicines11041025

Osmanović Barilar J, Babić Perhoč A, Knezović A, Homolak J, Virag D, Šalković Petrišić M. The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease. Biomedicines [Internet]. 27.03.2023. [pristupljeno 29.12.2024.];11(4). doi: 10.3390/biomedicines11041025

J. Osmanović Barilar, A. Babić Perhoč, A. Knezović, J. Homolak, D. Virag i M. Šalković Petrišić, "The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease", Biomedicines, vol. 11, br. 4, Ožujak 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:695960. [Citirano: 29.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:695960
Podaci o radu
Naslov (engleski)The Effect of the Sodium - Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease
AutorJelena Osmanović Barilar
AutorAna Babić Perhoč
AutorAna Knezović
AutorJan Homolak
AutorDavor Virag
AutorMelita Šalković-Petrišić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA TEMELJNU I KLINIČKU FARMAKOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Farmakologija
Sažetak (engleski)
Type 2 diabetes mellitus increases the risk of sporadic Alzheimer’s disease (sAD), and antidiabetic drugs, including the sodium–glucose cotransporter inhibitors (SGLTI), are being studied as possible sAD therapy. We have explored whether the SGLTI phloridzin may influence metabolic and cognitive parameters in a rat model of sAD. Adult male Wistar rats were randomized to a control (CTR), an sAD-model group induced by intracerebroventricular streptozotocin (STZ-icv; 3 mg/kg), a CTR+SGLTI, or an STZ-icv+SGLTI group. Two-month-long oral (gavage) SGLTI treatment (10 mg/kg) was initiated 1 month after STZ-icv and cognitive performance tested prior to sacrifice. SGLTI treatment significantly decreased plasma glucose levels only in the CTR group and failed to correct STZ-icv-induced cognitive deficit. In both the CTR and STZ-icv groups, SGLTI treatment diminished weight gain, decreased amyloid beta (Aβ) 1-42 in duodenum, and decreased the plasma levels of total glucagon-like peptide 1 (GLP-1), while the levels of active GLP-1, as well as both total and active glucose-dependent insulinotropic polypeptide, remained unchanged, compared to their respective controls. The increment in GLP-1 levels in the cerebrospinal fluid and its effect on Aβ 1-42 in duodenum could be one of the molecular mechanisms by which SGLTIs indirectly induce pleiotropic beneficial effects.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBiomedicines
Brojčani podacivol. 11, br. 4, 1025
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines11041025
URN:NBNurn:nbn:hr:105:695960
Datum objave publikacije2023-03-27
ProjektŠifra: IP-2018-01-8938
Naziv (hrvatski): Mehanizmi nutrijentom posredovanih učinaka endogenog glukagonu sličnog peptida-1 na kognitivne i metaboličke poremećaje u eksperimentalnim modelima neurodegenerativnih bolesti
Kratica: NutrientGLP-1
Voditelj: Melita Šalković-Petrišić
Pravna nadležnost: Hrvatska
Financijer: HRZZ
Linija financiranja: IP
ProjektŠifra: KK.01.1.1.01.0007
Naziv (engleski): Eksperimentalna i klinička istraživanja hipoksijsko-ishemijskog oštećenja mozga u perinatalnoj i odrasloj dobi
Voditelj: Ivica Kostović
Pravna nadležnost: eu
Financijer: EK
URL dokumentahttps://www.mdpi.com/2227-9059/11/4/1025
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-10-27 08:12:32